急性心不全治療ガイドライン（2011年改訂版）
Guidelines for Treatment of Acute Heart Failure（ JCS 2011）
Guidelines for Treatment of Acute Heart Failure（ JCS 2011）
201. Lemery R, Smith HC, Giuliani ER, et al. Prognosis in rupture of the ventricular septum after acute myocardial infarction and role of early surgical
intervention. Am J Cardiol 1992; 70: 147-151.
202. 泰江弘文．心不全と神経体液性因子（泰江弘文編）．医学書院 1999：1-11.
203. 木之下正彦. 心不全と循環ペプチド．CARDIAC PRACTICE 1999；10：259-263.
204. Fonarow GC, Abraham WT, Albert NM, et al.; OPTIMIZEHF Investigators and Coordinators. Influence of beta-blocker continuation or withdrawal on
outcomes in patients hospitalized with heart failure: findings from the OPTIMIZEHF program. J Am Coll Cardiol 2008; 52: 190-199.
205. Fearon WF, Shah M, Ng M, et al. Predictive value of the index of microcirculatory resistance in patients with STsegment elevation myocardial
infarction. J Am Coll Cardiol 2008; 51: 560-565.
206. Lorell BH, Isoyama S, Grice WN, et al. Effects of ouabain and isoproterenol on left ventricular diastolic function during low-flow ischemia in isolated,
blood-perfused rabbit hearts. Circ Res 1988; 63: 457-467.
207. Isoyama S, Apstein CS, Wexler LF, et al. Acute decrease in left ventricular diastolic chamber distensibility during simulated angina in isolated hearts.
Circ Res 1987; 61: 925- 933.
208. Slezak J, Tribulova N, Okruhlicova L, et al. Hibernating myocardium: pathophysiology, diagnosis, and treatment. CanJ Physiol Pharmacol 2009; 87:
252-265.
209. Badiwala MV, Verma S, Rao V. Surgical Management of Ischemic Mitral Regurgitation. Circulation 2009; 120: 1287- 1293
210. 日本高血圧治療学会高血圧治療ガイドライン作成委員会．高血圧治療ガイドライン 2009．ライフサイエンス，東京 2009.
211. Grossman E, Messerli FH, Grodzicki T, et al. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies
and pseudoemergencies? JAMA 1996; 276: 1328-1331.
212. Shah JS, Esteban MT, Thaman R, et al. Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-
obstructive hypertrophic cardiomyopathy. Heart 2008; 94: 1288-1294.
213. Kajimoto K, Imai T, Minami Y, et al. Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic
cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline. Am J Cardiol; 106: 1307-1312.
214. Sorajja P, Valeti U, Nishimura RA, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2008; 118: 131-
139.
215. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J
Med 2000; 342: 1077-1084.
216. 循環器病の診断と治療に関するガイドライン．急性およ び慢性心筋炎の診断・治療に関するガイドライン（2009年改訂版）．
http://www.j-circ.or.jp/guideline/pdf/JCS2009_izumi_h.pdf
217. Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis. Natural history and treatment. N Engl J Med 1997; 336: 1860-1866.
218. 大内田昌直，今泉勉．劇症型心筋炎の治療―ステロイド療法．劇症型心筋炎の臨床．和泉徹編．医学書院（東京）2002；71-80.
219. Kodama M, Okura Y, Hirono S, et al. A new scoring system to predict the efficacy of steroid therapy for patients with acute myocarditis- a
retrospective study. Jpn Circ J 1998; 62:715-720.
220. Kato S, Morimoto S, Hiramitsu S, et al. Successful highdose intravenous immunoglobulin therapy for a patient with fulminant myocarditis. Heart
Vessels 2007; 22: 48-51.
221. Robinson JL, Hartling L, Crumley E, et al. A systematic review of intravenous gamma globulin for therapy of acute myocarditis. BMC Cardiovasc
Disord 2005; 5: 12.
222. 日本循環器学会学術委員会（1997～1999 年度報告）．心肺補助循環を用いた劇症型心筋炎の治療と予後に関する調査研究．Jpn Circ J 2000；64，Suppl．I：
985-992.
223. 循環器病の診断と治療に関するガイドライン．弁膜疾患の非薬物治療に関するガイドライン（2007年改訂版）．
http://www.j-circ.or.jp/guideline/pdf/JCS2007_matsuda_h.pdf
224. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the
American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines
for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular
Angiography and Interventions, and Society of Thoracic Surgeons. Bonow RO, Carabello BA, Chatterjee K, et al.; American College of Cardiology/
American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 52: e1-142.
225. The National Heart, Lung, and Blood Institute Balloon Valvuloplasty Registry Participants. Multicenter experience with balloon mitral
commissurotomy.
NHLBI Balloon Valvuloplasty Registry Report on immediate and 30-day follow-up results. Circulation 1992; 85: 448-461.
226. Arora R, Nair M, Kalra GS, et al. Immediate and long-term results of balloon and surgical closed mitral valvotomy: a randomized comparison study.
Am Heart J 1993; 125: 1091-1094.
227. Kelly TA, Rothbart RM, Cooper CM, et al. Comparison of outcome of asymptomatic to symptomatic patients older than 20 years of age with valvular
aortic stenosis. Am J Cardiol1998; 61: 123-130.
228. Lieberman EB, Bashore TM, Hermiller JB, et al. Balloon aortic Valvuloplasty in adults: failure of procedure to improve long-term survival. J Am Coll
Cardiol 1995; 26: 1522-1528.
229. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA
2004; 292: 1555-1562.
230. Garty M, Cohen E, Zuchenko A, et al.; Heart Failure Survey in ISrael (HFSIS) Investigators. Blood transfusion for acute decompensated heart failure-
friend or foe? Am Heart J 2009; 158: 653-658.
231. Damman K, Navis G, Smilde TD, et al. Decreased cardiac output, venous congestion and the association wit ｈ renal impairment in patients with
cardiac dysfunction. Eur J Heart Fail 2007; 9: 872-878. Epub 2007 Jun 22.
232. Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure.
J Am Coll Cardiol2009; 53: 589-596.
233. Damman K, van Deursen VM, Navis G, et al. Increased central venous pressure is associated with impaired renal function and mortality in a broad
spectrum of patients with cardiovascular disease. J Am Coll Cardiol 2009; 53: 582-588.
234. Sezai A, Hata M, Niino T, et al. Influence of continuous infusion of low-dose human atrial natriuretic peptide on renal function during cardiac surgery: a
randomized controlledstudy. J Am Coll Cardiol 2009; 54: 1058-1064.
235. Morikawa S, Sone T, Tsuboi H, et al. Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide. J Am
Coll Cardiol 2009; 53:1040-1046.
236. Nigwekar SU, Navaneethan SD, Parikh CR, et al. Atrial natriuretic peptide for management of acute kidney injury: a systematic review and meta-
analysis. Clin J Am Soc Nephrol 2009; 4: 261-272.
237. Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. Circulation 2010; 121: 2592-2600.
238. Seeto RK, Fenn B, Rockey DC. Ischemic hepatitis: clinical presentation and pathogenesis. Am J Med 2000; 109: 109- 113.
239. Russell SD, Rogers JG, Milano CA, et al.; HeartMate II Clinical Investigators. Renal and hepatic function improve in advanced heart failure patients
during continuous-flow support with the HeartMate II left ventricular assist device. Circulation 2009; 120: 2352-2357. Epub 2009 Nov 23.
240. Shinagawa H, Inomata T, Koitabashi T, Nakano H, Takeuchi I, Osaka T, Nishii M, Takehana H, et al. Increased serum bilirubin levels coincident with
heart failure decompensation indicate the need for intravenous inotropic agents. Int Heart J 2007; 48: 195-204.
241. Matthews JC, Pagani FD, Haft JW, et al. Model for endstage liver disease score predicts left ventricular assist device operative transfusion
requirements, morbidity, and mortality. Circulation 2010; 121: 214-220.
242. Kavarana MN, Pessin-Minsley MS, Urtecho J, et al. Right ventricular dysfunction and organ failure in left ventricular assist device recipients: a
continuing problem. Ann Thorac Surg 2002; 73: 745-750.
243. 日本呼吸器学会 成人院内肺炎診療ガイドライン作成委 員会．呼吸器感染症に関するガイドライン．日本呼吸器学会．杏林社，東京 2008.
244. Shinbane JS, Wood MA, Jensen DN, et al. Tachycardiainduced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol
1997; 29: 709-715.
245. Maisel WH, Stevenson LW. Atrial fibrillation: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003; 91: 2D-8D.
246. Spinale FG, Hendrick DA, Crawford FA, et al. Chronic supraventricular tachycardia causes ventricular dysfunction and subendocardial injury in swine.
Am J Physiol 1990; 259:H218-229.
247. O’Brien PJ, Ianuzzo CD, Moe GW, et al. Rapid ventricular pacing of dogs to heart failure: biochemical and physiological studies. Can J Physiol
Pharmacol 1990; 68: 34-39.
248. Shannon RP, Komamura K, Shen YT, et al. Impaired regional subendocardial coronary flow reserve in conscious dogs with pacing-induced heart
failure. Am J Physiol 1993;265: H801-809.
249. Per reaul t CL, Shannon RP, Komamura K, et al . Abnormalities in intracellular calcium regulation and contractile function in myocardium from dogs
with pacinginduced heart failure. J Clin Invest 1992; 89: 932-938.
250. Kiuchi K, Shannon RP, Komamura K, et al. Myocardial beta-adrenergic receptor function during the development of pacing-induced heart failure. J Clin
Invest 1993; 91: 907-914.
251. Marzo KP, Frey MJ, Wilson JR, et al. Beta-adrenergic receptor-G protein-adenylate cyclase complex in experimental canine congestive heart failure
produced by rapid ventricular pacing. Circ Res 1991; 69: 1546-1556.
252. Nakamura R, Egashira K, Machida Y, et al. Probucol attenuates left ventricular dysfunction and remodeling in tachycardia-induced heart failure.
Circulation 2002; 106: 362-367.
253. Van Gelder IC, Crijns HJ, Blanksma PK, et al. Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of
chronic atrial fibrillation unassociated with cardiac valve disease. Am J Cardiol 1993; 72: 560-566.
254. Umana E, Solares CA, Alpert MA. Tachycardia induced cardiomyopathy. Am J Med 2003; 114: 51-55.
255. Wyse DG, Waldo AL, DiMarco JP, et al. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of
rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
256. Hsu LF, Jais P, Sanders P, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004; 351: 2373-2383.
257. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and
chronic heart failure. J Am Coll cardio 2007; 49: 171-180.
258. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005; 2:
8-11.
259. Rutten FH, Cramer MJ, Grobbee DE, et al. Unrecognized heart failure in elderly patients with stable Chronic obstructive pulmonary disease.
Eur Heart J 2005; 26: 1887- 1894.
260. Shelton RJ, Rigby AS, Cleland JG, et al. Effect of a community heart failure clinic on uptake of beta blockers by patients with obstructive airways
disease and heart failure. Heart 2006; 92: 331-336.
261. Tashkin DP, Celli B, Senn S, et al.; UPLIFT Study Investigators. A 4-year trial of tiotropiumin chronic obstructive pulmonary disease.
N Engl J Med 2008; 359: 1543-1554.
262. Calverley PM, Anderson JA, Celli B, et al.; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary
disease. N Engl J Med 2007; 356: 775-789.
263. Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, et al. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs
preserved ejection fraction -a report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD)-. Circ J 2009; 73: 1893-1900.
264. Miyagishima K, Hiramitsu S, Kimura H, et al. Long term prognosis of chronic heart failure: reduced vs preserved left ventricular ejection fraction. Circ
J 2009; 73: 92-99.
265. Yamamoto K, Sakata Y, Ohtani T, et al. Heart failure with preserved ejection fraction -what is known and unknown-. Circ J 2009; 73: 404-410.
266. Gandhi SK, Power s JC, Nomei r AM, et al . The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 2001; 344: 17-
22.
267. Nishio M, Sakata Y, Mano T, et al. Difference of clinical characteristics between hypertensive patients with and without diastolic heart failure: role of
diastolic dysfunction and renal insufficiency. Hypertens Res 2008; 31: 1865-1872.
268. Kawaguchi M, Hay I, Fetics B, et al. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction:
implications for systolic and diastolic reserve limitations. Circulation 2003; 107: 714-720.
269. Penicka M, Bartunek J, Trakalova H, et al. Heart failure with preserved ejection fraction in outpatients with unexplained dyspnea: a pressure-volume
loop analysis. J Am Coll Cardiol 2010; 55: 1701-1710.
270. Yamaguchi H, Yoshida J, Yamamoto K, et al. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of
ventricular hypertrophy. J Am Coll Cardiol. 2004; 43: 55-60.
271. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358: 2667-2677.
272. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the
CHARMPreserved Trial. Lancet 2003; 362: 777-781.
273. Cleland JGF, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338-
2345.
274. van Veldhuisen DJ, Cohen-Solal A, Böhm M, et al. Betablockade with nebivolol in elderly heart failure patients with impaired and preserved left
ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart
Failure). J Am Coll Cardiol 2009; 53: 2150-2158.
275. Blair JE, Zannad F, Konstam MA, et al. EVEREST Inves t igator s . Cont inental di fferences in cl inical characteristics, management, and outcomes
in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonist Heart Failure:
Outcome Study with Tolvaptan) program. J Am Coll Cardiol 2008; 52: 1640-1648.
276. O’Connor CM, Miller AB, Blair JE, et al. Efficacy of Vasopressin Antagonist heart Failure Outcome Study with Tolvaptan (EVEREST) investigators.
Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results
from Efficacy of Vasopressin Antagonist Heart Failure Outcome Study with Tolvaptan (EVEREST) program. Am Heart J 2010; 159: 841-849. e1.
277. Costanzo MR, Saltzberg MT, Jessup M, et al. Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart
Failure (UNLOAD) Investigators. Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with
decompensated heart failure: results from UNLOAD. J Card Fail 2010; 16: 277-278.
278. Costanzo MR. Ultrafiltration in the management of heart failure. Curr Opin Crit Care 2008; 14: 524-530.
279. Jaski BE, Fifer MA, Wright RF, et al. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. J Clin
Invest
1985; 75: 643-649.
280. Campana C, et al. The evaluation of right ventricular performance in different clinical models of heart failure. EHJ 2004; 6 suppl. F: F61-67.
281. Voelkel NK, et al. Right Ventricular Function and Failure: Report of a NHLBI Working Group on Cellular and Molecular Mechanisms of Right Heart
Failure. Circulation 2006; 114: 1883-1891.
282. Ochiai Y, et al. Predictors of Severe right ventricular failure after implantable LVAD insertion. Circulation 2002; 106 [Suppl I]: I-198-202.
283. 循環器病の診断と治療に関するガイドライン．肺高血圧症治療ガイドライン（2006年改訂版）．http://www.j-circ.or.jp/guideline/pdf/JCS2006_nakano_h.pdf
284. Flapan AD, Davies E, Waugh C, et al. Acute administration of captopril lowers the natriuretic and diuretic response to a loop diuretic in patients with
chronic heart failure. Eur Heart J 1991; 12: 924-927.
285. Elkayam U JJ, Shotan A, Bokhari S, et al. Double-blind, placebo-controlled study to evaluate the effect of organic nitrates in patients with chronic
heart failure treated with angiotensin-converting enzyme inhibition. Am Heart J 1999; 99: 2652-2657.
286. Gartis WA, O’Connor CM, Gallup DS, et al. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure. J Am Coll
Cardiol 2004; 43: 1534-1541.
287. Hernandez AF, Hammill BG, O’Connor CM, et al. Clinical effectiveness of beta-blockers in heart failure. J Am Coll Cardiol 2009; 53: 184-1923.
288. Yoshikawa T, Baba A, Suzuki M, et al.; for the Keio Interhospital Cardiology Study (KICS) Group. Effectiveness of carvedilol alone versus
carvedilol+pimobendan for severe congestive heart failure. Am J Cardiol 2000; 85: 1495-1497.
289. Stevenson LW, Massie BM, Franis G. Optimizing therapy for complex or refractory heart failure: a management algorithm. Am Heart J 1998; 135 (6 Pt
2 Suppl): S293-S309.
290. 小澤竹俊．ターミナル患者への対応．心不全を予防する 発症させない，再発させないための診療ストラテジー（和 泉徹, 筒井裕之，編集）．中山書店 2006：
343-350.
291. 村田久行．終末期がん患者のスピリチュアルペインとそのケア；アセスメントとケアのための概念的枠組みの構築．緩和医療学．2003；5：157-165.
292. 小澤竹俊．スピリチュアルケアの理論的なアプローチ．臨床看護 2004；30：1076-1086.